Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


Articles published in Oncogene

Retrieve available abstracts of 93 articles:
HTML format
Text format



Single Articles


    April 2019
  1. DUAN L, Perez RE, Chastain PD 2nd, Mathew MT, et al
    JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells.
    Oncogene. 2019 Apr 9. pii: 10.1038/s41388-019-0814.
    PubMed     Text format     Abstract available


    March 2019
  2. CASADO-MEDRANO V, Barrio-Real L, Wang A, Cooke M, et al
    Distinctive requirement of PKCepsilon in the control of Rho GTPases in epithelial and mesenchymally transformed lung cancer cells.
    Oncogene. 2019 Mar 28. pii: 10.1038/s41388-019-0796.
    PubMed     Text format     Abstract available


    February 2019
  3. ZHANG H, Wang Y, Dou J, Guo Y, et al
    Acetylation of AGO2 promotes cancer progression by increasing oncogenic miR-19b biogenesis.
    Oncogene. 2019;38:1410-1431.
    PubMed     Text format     Abstract available


  4. DE BOER HR, Pool M, Joosten E, Everts M, et al
    Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition.
    Oncogene. 2019;38:1477-1488.
    PubMed     Text format     Abstract available


  5. YONESAKA K, Takegawa N, Watanabe S, Haratani K, et al
    An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC.
    Oncogene. 2019;38:1398-1409.
    PubMed     Text format     Abstract available


  6. LIN SC, Chung CH, Chung CH, Kuo MH, et al
    OCT4B mediates hypoxia-induced cancer dissemination.
    Oncogene. 2019;38:1093-1105.
    PubMed     Text format     Abstract available


  7. BOUDRIA A, Abou Faycal C, Jia T, Gout S, et al
    VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a beta1 integrin/VEGFR autocrine loop.
    Oncogene. 2019;38:1050-1066.
    PubMed     Text format     Abstract available


  8. FANG L, Wu S, Zhu X, Cai J, et al
    MYEOV functions as an amplified competing endogenous RNA in promoting metastasis by activating TGF-beta pathway in NSCLC.
    Oncogene. 2019;38:896-912.
    PubMed     Text format     Abstract available


    January 2019
  9. CAO J, Zhu Z, Wang H, Nichols TC, et al
    Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer.
    Oncogene. 2019 Jan 30. pii: 10.1038/s41388-019-0708.
    PubMed     Text format     Abstract available


  10. LIU L, Yang Y, Liu S, Tao T, et al
    EGF-induced nuclear localization of SHCBP1 activates beta-catenin signaling and promotes cancer progression.
    Oncogene. 2019;38:747-764.
    PubMed     Text format     Abstract available


  11. HAMAIDI I, Coquard C, Danilin S, Dormoy V, et al
    The Lim1 oncogene as a new therapeutic target for metastatic human renal cell carcinoma.
    Oncogene. 2019;38:60-72.
    PubMed     Text format     Abstract available


    December 2018
  12. WIESWEG M, Kasper S, Worm K, Herold T, et al
    Impact of RAS mutation subtype on clinical outcome-a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer.
    Oncogene. 2018 Dec 19. pii: 10.1038/s41388-018-0634.
    PubMed     Text format     Abstract available


  13. SHIRAI YT, Mizutani A, Nishijima S, Horie M, et al
    CNOT3 targets negative cell cycle regulators in non-small cell lung cancer development.
    Oncogene. 2018 Dec 10. pii: 10.1038/s41388-018-0603.
    PubMed     Text format     Abstract available


  14. GIANNI M, Terao M, Kurosaki M, Paroni G, et al
    S100A3 a partner protein regulating the stability/activity of RARalpha and PML-RARalpha in cellular models of breast/lung cancer and acute myeloid leukemia.
    Oncogene. 2018 Dec 7. pii: 10.1038/s41388-018-0599.
    PubMed     Text format     Abstract available


  15. CAI L, Lin S, Girard L, Zhou Y, et al
    LCE: an open web portal to explore gene expression and clinical associations in lung cancer.
    Oncogene. 2018 Dec 7. pii: 10.1038/s41388-018-0588.
    PubMed     Text format     Abstract available


  16. TESSARI A, Parbhoo K, Pawlikowski M, Fassan M, et al
    RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients.
    Oncogene. 2018;37:6463-6476.
    PubMed     Text format     Abstract available


  17. OHNO Y, Shingyoku S, Miyake S, Tanaka A, et al
    Differential regulation of the sphere formation and maintenance of cancer-initiating cells of malignant mesothelioma via CD44 and ALK4 signaling pathways.
    Oncogene. 2018;37:6357-6367.
    PubMed     Text format     Abstract available


    November 2018
  18. FAN Z, Yang J, Zhang D, Zhang X, et al
    The risk variant rs884225 within EGFR impairs miR-103a-3p's anti-tumourigenic function in non-small cell lung cancer.
    Oncogene. 2018 Nov 23. pii: 10.1038/s41388-018-0576.
    PubMed     Text format     Abstract available


  19. BEST SA, Harapas CR, Kersbergen A, Rathi V, et al
    FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium.
    Oncogene. 2018;37:6096-6104.
    PubMed     Text format     Abstract available


  20. OOKI A, Dinalankara W, Marchionni L, Tsay JJ, et al
    Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma.
    Oncogene. 2018;37:5967-5981.
    PubMed     Text format     Abstract available


    October 2018
  21. LEONG TL, Gayevskiy V, Steinfort DP, De Massy MR, et al
    Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naive, metastatic lung cancer.
    Oncogene. 2018 Oct 22. pii: 10.1038/s41388-018-0536.
    PubMed     Text format     Abstract available


  22. SHIMIZU M, Tanaka N
    IL-8-induced O-GlcNAc modification via GLUT3 and GFAT regulates cancer stem cell-like properties in colon and lung cancer cells.
    Oncogene. 2018 Oct 10. pii: 10.1038/s41388-018-0533.
    PubMed     Text format     Abstract available


  23. KIM Y, Shiba-Ishii A, Nakagawa T, Iemura SI, et al
    Stratifin regulates stabilization of receptor tyrosine kinases via interaction with ubiquitin-specific protease 8 in lung adenocarcinoma.
    Oncogene. 2018;37:5387-5402.
    PubMed     Text format     Abstract available


  24. DI MODUGNO F, Spada S, Palermo B, Visca P, et al
    hMENA isoforms impact NSCLC patient outcome through fibronectin/beta1 integrin axis.
    Oncogene. 2018;37:5605-5617.
    PubMed     Text format     Abstract available


  25. LEE GW, Park JB, Park SY, Seo J, et al
    The E3 ligase C-CBL inhibits cancer cell migration by neddylating the proto-oncogene c-Src.
    Oncogene. 2018;37:5552-5568.
    PubMed     Text format     Abstract available


    September 2018
  26. YU W, Ding J, He M, Chen Y, et al
    Estrogen receptor beta promotes the vasculogenic mimicry (VM) and cell invasion via altering the lncRNA-MALAT1/miR-145-5p/NEDD9 signals in lung cancer.
    Oncogene. 2018 Sep 24. pii: 10.1038/s41388-018-0463.
    PubMed     Text format     Abstract available


  27. LIN YP, Wu JI, Tseng CW, Chen HJ, et al
    Gjb4 serves as a novel biomarker for lung cancer and promotes metastasis and chemoresistance via Src activation.
    Oncogene. 2018 Sep 3. pii: 10.1038/s41388-018-0471.
    PubMed     Text format     Abstract available


    August 2018
  28. LIANG SQ, Buhrer ED, Berezowska S, Marti TM, et al
    mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer.
    Oncogene. 2018 Aug 31. pii: 10.1038/s41388-018-0479.
    PubMed     Text format     Abstract available


  29. YOCHUM ZA, Cades J, Wang H, Chatterjee S, et al
    Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.
    Oncogene. 2018 Aug 31. pii: 10.1038/s41388-018-0482.
    PubMed     Text format     Abstract available


  30. KIM IK, McCutcheon JN, Rao G, Liu SV, et al
    Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer.
    Oncogene. 2018 Aug 9. pii: 10.1038/s41388-018-0429.
    PubMed     Text format     Abstract available


  31. WEEDEN CE, Ah-Cann C, Holik AZ, Pasquet J, et al
    Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition.
    Oncogene. 2018;37:4475-4488.
    PubMed     Text format     Abstract available


  32. YUE J, Lv D, Wang C, Li L, et al
    Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin beta3.
    Oncogene. 2018;37:4300-4312.
    PubMed     Text format     Abstract available


    July 2018
  33. LU CH, Yeh DW, Lai CY, Liu YL, et al
    USP17 mediates macrophage-promoted inflammation and stemness in lung cancer cells by regulating TRAF2/TRAF3 complex formation.
    Oncogene. 2018 Jul 23. pii: 10.1038/s41388-018-0411.
    PubMed     Text format     Abstract available


  34. GLUCK AA, Orlando E, Leiser D, Poliakova M, et al
    Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1alpha levels under hypoxia.
    Oncogene. 2018;37:4181-4196.
    PubMed     Text format     Abstract available


  35. CROSSLAND DL, Denning WL, Ang S, Olivares S, et al
    Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models.
    Oncogene. 2018;37:3686-3697.
    PubMed     Text format     Abstract available


  36. TANG Q, Lu J, Zou C, Shao Y, et al
    CDH4 is a novel determinant of osteosarcoma tumorigenesis and metastasis.
    Oncogene. 2018;37:3617-3630.
    PubMed     Text format     Abstract available


    June 2018
  37. WANG K, Ji W, Yu Y, Li Z, et al
    FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer.
    Oncogene. 2018 Jun 1. pii: 10.1038/s41388-018-0311.
    PubMed     Text format     Abstract available


  38. LAI SC, Phelps CA, Short AM, Dutta SM, et al
    Thyroid transcription factor 1 enhances cellular statin sensitivity via perturbing cholesterol metabolism.
    Oncogene. 2018;37:3290-3300.
    PubMed     Text format     Abstract available


  39. DANKNER M, Rose AAN, Rajkumar S, Siegel PM, et al
    Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
    Oncogene. 2018;37:3183-3199.
    PubMed     Text format     Abstract available


    May 2018
  40. JI X, Qian J, Rahman SMJ, Siska PJ, et al
    xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression.
    Oncogene. 2018 May 23. pii: 10.1038/s41388-018-0307.
    PubMed     Text format     Abstract available


  41. ZHAO C, Li Y, Qiu W, He F, et al
    C5a induces A549 cell proliferation of non-small cell lung cancer via GDF15 gene activation mediated by GCN5-dependent KLF5 acetylation.
    Oncogene. 2018 May 18. pii: 10.1038/s41388-018-0298.
    PubMed     Text format     Abstract available


  42. WANG PS, Chou CH, Lin CH, Yao YC, et al
    A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer.
    Oncogene. 2018 May 14. pii: 10.1038/s41388-018-0293.
    PubMed     Text format     Abstract available


  43. CHEN A, Sceneay J, Godde N, Kinwel T, et al
    Intermittent hypoxia induces a metastatic phenotype in breast cancer.
    Oncogene. 2018 May 1. pii: 10.1038/s41388-018-0259.
    PubMed     Text format     Abstract available


  44. ITOH H, Kadomatsu T, Tanoue H, Yugami M, et al
    TET2-dependent IL-6 induction mediated by the tumor microenvironment promotes tumor metastasis in osteosarcoma.
    Oncogene. 2018;37:2903-2920.
    PubMed     Text format     Abstract available


  45. REHRAUER H, Wu L, Blum W, Pecze L, et al
    How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations.
    Oncogene. 2018;37:2645-2659.
    PubMed     Text format     Abstract available


    April 2018
  46. WANG S, Jia M, He Z, Liu XS, et al
    APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer.
    Oncogene. 2018 Apr 26. pii: 10.1038/s41388-018-0245.
    PubMed     Text format     Abstract available


  47. TOMOSHIGE K, Guo M, Tsuchiya T, Fukazawa T, et al
    An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo.
    Oncogene. 2018 Apr 17. pii: 10.1038/s41388-018-0240.
    PubMed     Text format     Abstract available


  48. NEWMAN JH, Augeri DJ, NeMoyer R, Malhotra J, et al
    Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer.
    Oncogene. 2018 Apr 6. pii: 10.1038/s41388-018-0156.
    PubMed     Text format     Abstract available


  49. PENTIMALLI F, Forte IM, Esposito L, Indovina P, et al
    RBL2/p130 is a direct AKT target and is required to induce apoptosis upon AKT inhibition in lung cancer and mesothelioma cell lines.
    Oncogene. 2018 Apr 2. pii: 10.1038/s41388-018-0214.
    PubMed     Text format     Abstract available


    March 2018
  50. MONTERISI S, Riso PL, Russo K, Bertalot G, et al
    HOXB7 overexpression in lung cancer is a hallmark of acquired stem-like phenotype.
    Oncogene. 2018 Mar 26. pii: 10.1038/s41388-018-0229.
    PubMed     Text format     Abstract available


  51. TANG J, Chen H, Wong CC, Liu D, et al
    DEAD-box helicase 27 promotes colorectal cancer growth and metastasis and predicts poor survival in CRC patients.
    Oncogene. 2018 Mar 14. pii: 10.1038/s41388-018-0196.
    PubMed     Text format     Abstract available


  52. MEDER L, Konig K, Dietlein F, Macheleidt I, et al
    LIN28B enhanced tumorigenesis in an autochthonous KRAS(G12V)-driven lung carcinoma mouse model.
    Oncogene. 2018 Mar 5. pii: 10.1038/s41388-018-0158.
    PubMed     Text format     Abstract available


    February 2018
  53. LAI Q, Wang H, Li A, Xu Y, et al
    Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells.
    Oncogene. 2018 Feb 9. pii: 10.1038/s41388-018-0125.
    PubMed     Text format     Abstract available


    January 2018
  54. ZHENG X, Chi J, Zhi J, Zhang H, et al
    Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration.
    Oncogene. 2018;37:502-511.
    PubMed     Text format     Abstract available


  55. WELCKER D, Jain M, Khurshid S, Jokic M, et al
    AATF suppresses apoptosis, promotes proliferation and is critical for Kras-driven lung cancer.
    Oncogene. 2018 Jan 11. pii: 10.1038/s41388-017-0054.
    PubMed     Text format     Abstract available


  56. CORKERY DP, Clarke LE, Gebremeskel S, Salsman J, et al
    Loss of PRP4K drives anoikis resistance in part by dysregulation of epidermal growth factor receptor endosomal trafficking.
    Oncogene. 2018;37:174-184.
    PubMed     Text format     Abstract available


  57. CHIANG WF, Cheng TM, Chang CC, Pan SH, et al
    Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) promotes EGF receptor signaling of oral squamous cell carcinoma metastasis via the complex N-glycosylation.
    Oncogene. 2018;37:116-127.
    PubMed     Text format     Abstract available


  58. ORTH M, Unger K, Schoetz U, Belka C, et al
    Taxane-mediated radiosensitization derives from chromosomal missegregation on tripolar mitotic spindles orchestrated by AURKA and TPX2.
    Oncogene. 2018;37:52-62.
    PubMed     Text format     Abstract available


    November 2017
  59. SZYMICZEK A, Carbone M, Pastorino S, Napolitano A, et al
    Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma.
    Oncogene. 2017;36:6501-6507.
    PubMed     Text format     Abstract available


  60. ZHONG Y, Yang J, Xu WW, Wang Y, et al
    KCTD12 promotes tumorigenesis by facilitating CDC25B/CDK1/Aurora A-dependent G2/M transition.
    Oncogene. 2017;36:6177-6189.
    PubMed     Text format     Abstract available


  61. TORRENTE L, Sanchez C, Moreno R, Chowdhry S, et al
    Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses.
    Oncogene. 2017;36:6204-6212.
    PubMed     Text format     Abstract available


  62. TRINIDAD AG, Whalley N, Rowlinson R, Delpuech O, et al
    Pyruvate dehydrogenase kinase 4 exhibits a novel role in the activation of mutant KRAS, regulating cell growth in lung and colorectal tumour cells.
    Oncogene. 2017;36:6164-6176.
    PubMed     Text format     Abstract available


    October 2017
  63. REN T, Zhang H, Wang J, Zhu J, et al
    MCU-dependent mitochondrial Ca2+ inhibits NAD+/SIRT3/SOD2 pathway to promote ROS production and metastasis of HCC cells.
    Oncogene. 2017;36:5897-5909.
    PubMed     Text format     Abstract available


  64. IVANOV AA, Gonzalez-Pecchi V, Khuri LF, Niu Q, et al
    OncoPPi-informed discovery of mitogen-activated protein kinase kinase 3 as a novel binding partner of c-Myc.
    Oncogene. 2017;36:5852-5860.
    PubMed     Text format     Abstract available


  65. SPOLVERINI A, Fuchs G, Bublik DR, Oren M, et al
    let-7b and let-7c microRNAs promote histone H2B ubiquitylation and inhibit cell migration by targeting multiple components of the H2B deubiquitylation machinery.
    Oncogene. 2017;36:5819-5828.
    PubMed     Text format     Abstract available


  66. CHHABRA Y, Wong HY, Nikolajsen LF, Steinocher H, et al
    A growth hormone receptor SNP promotes lung cancer by impairment of SOCS2-mediated degradation.
    Oncogene. 2017 Oct 2. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    September 2017
  67. KATO T, Sato T, Yokoi K, Sekido Y, et al
    E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells.
    Oncogene. 2017;36:5522-5531.
    PubMed     Text format     Abstract available


  68. ZHANG Y, Hu Y, Wang JL, Yao H, et al
    Proteomic identification of ERP29 as a key chemoresistant factor activated by the aggregating p53 mutant Arg282Trp.
    Oncogene. 2017;36:5473-5483.
    PubMed     Text format     Abstract available


  69. ROWSON-HODEL AR, Wald JH, Hatakeyama J, O'Neal WK, et al
    Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer.
    Oncogene. 2017 Sep 11. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  70. KIM M, Jang K, Miller P, Picon-Ruiz M, et al
    VEGFA links self-renewal and metastasis by inducing Sox2 to repress miR-452, driving Slug.
    Oncogene. 2017;36:5199-5211.
    PubMed     Text format     Abstract available


  71. CHEN G, Zhang B, Xu H, Sun Y, et al
    Suppression of Sirt1 sensitizes lung cancer cells to WEE1 inhibitor MK-1775-induced DNA damage and apoptosis.
    Oncogene. 2017 Sep 4. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  72. YAN F, Shen N, Pang J, Zhao N, et al
    A regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness.
    Oncogene. 2017 Sep 4. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    August 2017
  73. YURUGI H, Marini F, Weber C, David K, et al
    Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours.
    Oncogene. 2017;36:4778-4789.
    PubMed     Text format     Abstract available


    July 2017
  74. VELMURUGAN KR, Varghese RT, Fonville NC, Garner HR, et al
    High-depth, high-accuracy microsatellite genotyping enables precision lung cancer risk classification.
    Oncogene. 2017 Jul 31. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  75. GARNETT S, Dutchak KL, McDonough RV, Dankort D, et al
    p53 loss does not permit escape from BrafV600E-induced senescence in a mouse model of lung cancer.
    Oncogene. 2017 Jul 24. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  76. UMEDA Y, Hasegawa Y, Otsuka M, Ariki S, et al
    Surfactant protein D inhibits activation of non-small cell lung cancer-associated mutant EGFR and affects clinical outcomes of patients.
    Oncogene. 2017 Jul 24. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  77. WU DW, Lee MC, Hsu NY, Wu TC, et al
    FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-kappaB/Slug-mediated PUMA reduction.
    Oncogene. 2017 Jul 17. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  78. WANG J, Jia Y, Zhao S, Zhang X, et al
    BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.
    Oncogene. 2017 Jul 17. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    June 2017
  79. NOTO A, De Vitis C, Pisanu ME, Roscilli G, et al
    Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
    Oncogene. 2017 Jun 19. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  80. JEN J, Lin LL, Lo FY, Chen HT, et al
    Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.
    Oncogene. 2017 Jun 19. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  81. FENG J, Yang H, Zhang Y, Wei H, et al
    Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells.
    Oncogene. 2017 Jun 12. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  82. SZCZEPNY A, Rogers S, Jayasekara WSN, Park K, et al
    The role of canonical and non-canonical Hedgehog signaling in tumor progression in a mouse model of small cell lung cancer.
    Oncogene. 2017 Jun 5. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  83. LIAO SY, Chiang CW, Hsu CH, Chen YT, et al
    CK1delta/GSK3beta/FBXW7alpha axis promotes degradation of the ZNF322A oncoprotein to suppress lung cancer progression.
    Oncogene. 2017 Jun 5. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  84. LI H, Xiao N, Wang Y, Wang R, et al
    Smurf1 regulates lung cancer cell growth and migration through interaction with and ubiquitination of PIPKIgamma.
    Oncogene. 2017 Jun 5. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    May 2017
  85. WANG Q, Ma J, Lu Y, Zhang S, et al
    CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells.
    Oncogene. 2017 May 22. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  86. CHOI EJ, Jung BJ, Lee SH, Yoo HS, et al
    A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer.
    Oncogene. 2017 May 15. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    April 2017
  87. HSU YL, Hung JY, Chang WA, Lin YS, et al
    Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1.
    Oncogene. 2017 Apr 24. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  88. AMBROGIO C, Barbacid M, Santamaria D
    In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma.
    Oncogene. 2017;36:2309-2318.
    PubMed     Text format     Abstract available


  89. LU W, Cheng F, Yan W, Li X, et al
    Selective targeting p53WT lung cancer cells harboring homozygous p53 Arg72 by an inhibitor of CypA.
    Oncogene. 2017 Apr 10. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  90. OHM AM, Tan AC, Heasley LE, Reyland ME, et al
    Co-dependency of PKCdelta and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  91. JEN J, Lin LL, Lo FY, Chen HT, et al
    Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format    


  92. NOTO A, De Vitis C, Pisanu ME, Roscilli G, et al
    Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  93. SHAKYA R, Tarulli GA, Sheng L, Lokman NA, et al
    Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: